… weight of ∼1.5–2.0 kg during the treatment period, which is close to what we report here.
However, there was no significant effect of dapagliflozin treatment … most likely reflects a loss of …

… tolerability of 24 weeks of dapagliflozin treatment as add-on therapy … who had been treated
with sulphonylurea monotherapy. … dapagliflozin induces weight loss may relate to caloric loss …

… In conclusion, dapagliflozin as monotherapy in treatment-naïve people with early Type 2
diabetes … and low rates of hypoglycaemia with the added benefit of weight loss over 102 weeks. …

… that the weight loss observed in the dapagliflozin group was partly as a result of fat loss. …
, which might also indicate a modest fluid loss by dapagliflozin-mediated osmotic diuresis. …

… Dapagliflozin has a low risk of hypoglycaemia, although the … Dapagliflozin is not recommended
in patients with moderate … tolerability profile, dapagliflozin is a useful treatment option in …

… weight loss before starting dapagliflozin and lost less weight than patients without background
GLP1-RAs. Previous weight loss with a GLP1-RA might make further weight … body weight …

… weight by sex (P = .099), with greater weight loss for women vs men across all treatments
(… In conclusion, treatment with exenatide once weekly plus dapagliflozin reduced HbA1c and …

… , and diabetes treatments that work through insulin signaling are associated with weight gain.
The glucosuria-mediated weight loss observed with dapagliflozin as monotherapy or as an …

… treatment led to weight gain and more hypoglycemic episodes, dapagliflozin produced
significant weight loss … Dapagliflozin treatment was generally safe and well tolerated, but events …

… Body weight Dapagliflozin treatment results in body weight loss of 2–3 kg in patients with
type 2 diabetes (baseline body weight 80–90 kg) [Citation65]. According to an RCT involving …